MAP BioPharma
Case Study

MAP’s vision to accelerate patient access to medicines, devices and diagnostics is at the heart of everything we do.

Case study 4:

Securing a price rise for an existing medicine


  •  An increase in the cost of a raw material costs in our client’s product meant that the product was no longer profitable in the UK.

  •  The raw material was expected to remain expensive for some time and our client was keen to find out whether a price rise might be possible.


  •  A combination of MAP Online and MAP Consulting support helped to inform the client about the options available to them.

  •  We conducted confidential ‘no-name’ discussions with the Department of Health and Social Care to see whether a price rise might be feasible.

  •  We also reviewed the client’s latest annual financial return (AFR) to the DHSC and advised on their messaging and position in relation to the price rise.

  •  We supported the client in completing and submitting the paperwork associated with a price rise.


  •  Our client was successful in securing a price rise for their product at the target that they had wished to achieve.

Case study-diagram
CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52